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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
Cynatine
®
 and maintenance of normal joint mobility pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Roxlor Nutra LLC, submitted pursuant to Article 13(5) of Regulation (EC) No 
1924/2006 via the Competent Authority of Belgium, the Panel on Dietetic Products, Nutrition and Allergies 
(NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Cynatine
®
 and 
maintenance of normal joint mobility. The Panel considers that Cynatine
®
, which is a keratin powder extracted 
from sheep wool, is sufficiently characterised. The claimed effect proposed by the applicant refers to “joint 
flexibility”. The Panel considers that maintenance of normal joint mobility is a beneficial physiological effect. 
The applicant presented one unpublished human intervention study as being pertinent to the health claim. The 
Panel notes that the study was specifically designed to identify patients with clinical diagnosis of osteoarthritis, 
and considers that normal cells and tissues are genetically (gene expression) and functionally different from 
osteoarthritic cells and tissues, and therefore may respond differently to interventions with exogenous substances. 
In addition, the mechanisms involved in the onset and/or progression of osteoarthritis are largely unknown. It 
would have to be established, therefore, that an intervention which has an effect on the progression of the disease 
(in patients with osteoarthritis) would also have an effect on its onset (subjects without the disease). The Panel 
considers that no conclusions can be drawn from this study for the scientific substantiation of the claim. The 
Panel concludes that a cause and effect relationship has not been established between the consumption of 
Cynatine
®
 and maintenance of normal joint mobility. 
© European Food Safety Authority, 2012 
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SUMMARY 
Following an application from Roxlor Nutra LLC, submitted pursuant to Article 13(5) of Regulation 
(EC) No 1924/2006 via the Competent Authority of Belgium, the Panel on Dietetic Products, 
Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a 
health claim related to Cynatine
®
 and maintenance of normal joint mobility. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence and including a request for the protection of proprietary data. 
The food that is the subject of the health claim is Cynatine
®
, which is a keratin powder extracted from 
sheep wool. The Panel considers that Cynatine
®
 is sufficiently characterised. 
The claimed effect proposed by the applicant refers to “joint flexibility”. The target population 
proposed by the applicant is healthy adults, and in particular healthy individuals with “sensitive 
joints”. The Panel considers that the health claim refers to the maintenance of joint mobility in 
subjects without chronic joint diseases, and does not include the treatment of chronic joint diseases. 
The Panel considers that maintenance of normal joint mobility is a beneficial physiological effect. 
The applicant presented one unpublished human intervention study as being pertinent to the health 
claim. 
The study was a randomised, double-blind, placebo-controlled parallel trial in which 50 subjects with 
clinical diagnosis of osteoarthritis of the knee were randomised to consume daily 500 mg of Cynatine 
FLX™ or placebo for 60 days. Inclusion criteria were 25-75 years of age, unilateral or bilateral 
osteoarthritis of the knee according to the American College of Rheumatology clinical criteria for the 
classification of idiopathic osteoarthritis of the knee, a total Western Ontario and McMaster 
Universities (WOMAC) osteoarthritis score of 15-75 (the worst score being 96) in the target knee, and 
ability to walk unassisted. 
The Panel notes that the study was specifically designed to identify patients with clinical diagnosis of 
osteoarthritis, and considers that normal cells and tissues are genetically (gene expression) and 
functionally different from osteoarthritic cells and tissues, and therefore may respond differently to 
interventions with exogenous substances. In addition, the mechanisms involved in the onset and/or 
progression of osteoarthritis are largely unknown. It would have to be established, therefore, that an 
intervention which has an effect on the progression of the disease (in patients with osteoarthritis) 
would also have an effect on its onset (subjects without the disease). The Panel considers that no 
conclusions can be drawn from this study for the scientific substantiation of the claim. 
The Panel notes that no studies from which conclusions could be drawn for the scientific 
substantiation of the claim were provided by the applicant. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of Cynatine
®
 and maintenance of normal joint mobility. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA  
 The application was received on 04/05/2012. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence and including a request for the protection of proprietary data. 
 On 31/05/2012, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
 The applicant provided the missing information on 10/07/2012. 
 The scientific evaluation procedure started on 17/07/2012. 
 On 26/10/2012, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application, and the 
clock was stopped on 01/11/2012, in compliance with Article 18(3) of Regulation (EC) 
No 1924/2006. 
 On 07/11/2012, EFSA received the requested information as submitted by the applicant and 
the clock was restarted, in compliance with Article 18(3) of Regulation (EC) No 1924/2006. 
 During its meeting on 28/11/2012, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to Cynatine
®
 and 
maintenance of normal joint mobility. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: Cynatine
®
 and maintenance of 
normal joint mobility. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of Cynatine
®
, a positive assessment of its safety, nor a decision on whether Cynatine
®
 is, or 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the 
framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
Cynatine
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Roxlor Nutra LLC, 1013 Centre Rd. Suite 106, Wilmington, 
DE-USA 19805. 
The application includes a request for the protection of proprietary data for one unpublished study 
(Wilson and Veghte, 2010), in accordance with Article 21 of Regulation (EC) No 1924/2006. 
Food/constituent as stated by the applicant 
According to the applicant, Cynatine
®
, which is a keratin powder extracted from sheep wool. 
Health relationship as claimed by the applicant 
According to the applicant, the health claim refers to the support of joint flexibility. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “daily consumption of 500 mg 
of Cynatine
®
 helps to support joint flexibility”. 
The following alternative wording was proposed: “helps support joint function by reducing pain and 
stiffness”. 
Specific conditions of use as proposed by the applicant 
The applicant has proposed an intake of 500 mg/day of Cynatine
®
 for 60 consecutive days, to be 
consumed with a large glass of plain water. The target population is healthy adults, and in particular 
healthy individuals with “sensitive joints”. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food that is the subject of the health claim is Cynatine
®
, which is a keratin powder extracted from 
sheep wool. 
Cynatine
®
 contains on average 72 g protein, 25.8 g ash and 2.2 g moisture per 100 g of the 
commercial product. The protein is extracted from New Zealand sheep wool and subsequently 
enzymatically hydrolysed into peptides, following a patented manufacturing process (WO 03/011894 
A1). Information on the typical amino acid profile and size distribution of the peptides, as well as 
information on the manufacturing process, batch to batch variability, stability and microbiological 
analysis was provided. 
The Panel considers that the food, Cynatine
®
, which is the subject of the health claim, is sufficiently 
characterised. 
2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant refers to “joint flexibility”. The target population 
proposed by the applicant is healthy adults, and in particular healthy individuals with “sensitive 
joints”. “Sensitive joints” was defined by the applicant as joints “in which some level of discomfort 
Cynatine
®
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(pain, stiffness or otherwise) is felt, but it is not to the point where the discomfort is debilitating or 
requires the use of medication”. The applicant also clarified that “it would not include any individuals 
who have been diagnosed as having any specific joint disease which would define them as unhealthy 
individuals”. 
The Panel considers that the health claim refers to the maintenance of joint mobility in subjects 
without chronic joint diseases, and does not include the treatment of chronic joint diseases. 
The Panel considers that maintenance of normal joint mobility is a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in PubMed, ScienceDirect, Google, Google Scholar, 
IBIDS, Scopus and Scirus using the search terms [(“Cynatine®”) AND (“osteoarthritis” OR “joint” 
OR “rheumatoid arthritis”)] to identify studies conducted with at least 500 mg/day of Cynatine®. No 
published studies were found. The Panel notes the limited scope of the literature search performed. 
The applicant presented one unpublished human intervention study as being pertinent to the health 
claim (Wilson and Veghte, 2010, unpublished, claimed as proprietary by the applicant). 
The study (Wilson and Veghte, 2010, unpublished) was a randomised, double-blind, placebo-
controlled parallel trial in which 50 subjects with clinical diagnosis of osteoarthritis (OA) of the knee 
were randomised to consume daily 500 mg of Cynatine FLX™ (n=25, 18 females, 52.6±10.0 years) 
or placebo (maltodextrin; n=25, 14 females, 52.3±9.5 years) for 60 days. Inclusion criteria were 
25-75 years of age, unilateral or bilateral OA of the knee according to the American College of 
Rheumatology clinical criteria for the classification of idiopathic OA of the knee (i.e. knee pain plus 
at least three out of the following six: age >50 years, stiffness <30 min, crepitus, bony tenderness, 
bony enlargement, no palpable warmth), a total Western Ontario and McMaster Universities 
(WOMAC) osteoarthritis score of 15-75 (the worst score being 96) in the target knee, and ability to 
walk unassisted (may use walking stick, crutch or knee brace). Exclusion criteria were use on a 
regular basis of prescription drugs other than acetaminophen (paracetamol) to control pain, and use of 
oral or topical prescription or over-the-counter medications (other than acetaminophen), or of 
“natural” products for pain relief, 48 hours prior to randomisation or during the trial. 
During the scientific evaluation, the Panel noted that the clinical tool used for the screening of the 
study subjects was designed to identify subjects with OA of the knee (Altman et al., 1986). EFSA 
highlighted to the applicant that the available scientific evidence does not establish that results 
obtained in patients with OA relating to the treatment of symptoms of this disease (e.g. erosion of 
articular cartilage, and reduced mobility of joints) can be extrapolated to the target population 
(subjects without the disease) for a claim on joint function (EFSA Panel on Dietetic Products, 
Nutrition and Allergies (NDA), 2012). In reply, the applicant argued that the lack of radiological 
confirmation of OA, and that acetaminophen was sufficient to control pain for the duration of the 
study could indicate that most of the subjects enrolled were healthy. The applicant also argued that 
even if the study population included some cases of OA, the results could be extrapolated to the target 
population for the claim because all subjects were able to live normal lives without medication. 
The Panel notes that the study was specifically designed to identify patients with clinical diagnosis of 
OA rather than to exclude them, and considers that normal cells and tissues are genetically (gene 
expression) and functionally different from osteoarthritic cells and tissues, and therefore may respond 
differently to interventions with exogenous substances (FDA, 2004a,b). In addition, the mechanisms 
involved in the onset and/or progression of OA are largely unknown. It would have to be established, 
therefore, that an intervention which has an effect on the progression of the disease (in patients with 
OA) would also have an effect on its onset (subjects without the disease) (FDA, 2004a,b). The Panel 
Cynatine
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considers that no conclusions can be drawn from this study for the scientific substantiation of the 
claim. 
The Panel notes that no studies from which conclusions could be drawn for the scientific 
substantiation of the claim were provided by the applicant. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of Cynatine
®
 and maintenance of normal joint mobility. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 
 The food, Cynatine®, which is the subject of the health claim, is sufficiently characterised. 
 The claimed effect proposed by the applicant refers to “joint flexibility”. The target 
population proposed by the applicant is healthy adults, and in particular healthy individuals 
with “sensitive joints”. The health claim refers to the maintenance of joint mobility in 
subjects without chronic joint diseases, and does not include the treatment of chronic joint 
diseases. Maintenance of normal joint mobility is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
Cynatine
®
 and maintenance of normal joint mobility. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on Cynatine
®
 and maintenance of normal joint mobility pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial No: 0349_BE). May 2012. Submitted 
by Roxlor Nutra, LLC. 
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GLOSSARY/ABBREVIATIONS 
OA  Osteoarthritis 
WOMAC Western Ontario and McMaster Universities 
